文献速递临床试验与 GCP流行病学与生物统计

一种用于心房颤动抗凝管理的新型共享决策(SDM)工具:前瞻性整群随机对照试验方案

A novel shared decision-making (SDM) tool for anticoagulation management in atrial fibrillation: protocol for a prospective, cluster randomized controlled trial.
PubMed 文献 · Trials · 2023-10-02

本研究为在中国上海8个社区卫生服务中心开展的前瞻性整群随机对照试验,纳入440例心房颤动患者,评估新型共享决策工具用于抗凝管理的有效性。SDM组通过新型SDM工具接受抗凝管理,对照组接受标准诊疗,随访至少2年。主要结局为任何出血事件,次要结局包括符合现行指南的卒中预防一致性、治疗目标范围内时间(TTR)、大出血和血栓事件发生率以及患者知识、依从性和满意度。

要点

  • 前瞻性整群随机对照试验,纳入上海8个社区卫生服务中心的440例心房颤动患者。
  • SDM组使用新型共享决策工具进行抗凝管理,对照组接受标准诊疗,随访至少2年。
  • 主要结局为任何出血事件,次要结局包括指南一致性、TTR、大出血和血栓事件及患者报告结局。

核心结论

  • 本研究将提供共享决策改善中国心房颤动患者口服抗凝药使用适当性的有效性证据。
  • 研究结果可能为中国及其他国家心房颤动和抗凝治疗管理指南与政策的制定提供信息。

研究设计与样本

  • 前瞻性整群随机对照试验,纳入中国上海8个社区卫生服务中心(整群)的440例心房颤动患者。
  • SDM组通过新型SDM工具接受抗凝管理,对照组接受标准诊疗。
  • 随访期至少2年。
  • 试验注册号ChiCTR2200062123,注册日期2022年7月23日。

主要发现

  • 主要结局为任何出血事件。
  • 次要结局包括根据现行指南的心房颤动卒中预防一致性、治疗目标范围内时间(TTR)、大出血和血栓事件的发生率,以及患者知识、依从性和满意度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia that requires anticoagulation therapy to prevent stroke. However, there is still a significant under-/over-treatment in stroke prevention for patients with AF. The adherence and the risk of bleeding associated with oral anticoagulation therapy (OACs) are major concerns. Shared decision-making (SDM) is an approach that involves patients and healthcare providers in making decisions about treatment options. This study aims to assess the effectiveness of a novel SDM tool for anticoagulation management in AF. METHODS: The study will be a prospective, cluster randomized controlled trial involving 440 patients with AF in 8 community health service centers (clusters) in Shanghai, China. The SDM group will receive anticoagulation management through the novel SDM tool, while the control group will receive standard care. The follow-up period will be at least 2 years. The primary outcome will be any bleeding event, while secondary outcomes include the accordance of stroke prophylaxis for AF according to the current guidelines, time in therapeutic range (TTR), the occurrences of major bleeding and thrombosis events, and patient knowledge, adherence, and satisfaction. DISCUSSION: This study will provide evidence of the effectiveness of shared decision-making in improving the appropriateness of OAC use in Chinese AF patients. The findings may inform the development of guidelines and policies for the management of AF and anticoagulation therapy in China and other countries. TRIAL REGISTRATION: ChiCTR ChiCTR2200062123. Registered on 23 July 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pan MM, Zhang C, Shen L, et al. A novel shared decision-making (SDM) tool for anticoagulation management in atrial fibrillation: protocol for a prospective, cluster randomized controlled trial. Trials. 2023. PMID: 37779187. doi:10.1186/s13063-023-07667-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。